Fig. 2From: Cost-effectiveness analysis of biologics for the treatment of chronic rhinosinusitis with nasal polyps in CanadaCost-effectiveness plane—Cost-effectiveness plane comparing dupilumab, mepolizumab, and omalizumab to revision surgeryBack to article page